Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

David A. Ehrmann to Hypoglycemic Agents

This is a "connection" page, showing publications David A. Ehrmann has written about Hypoglycemic Agents.

 
Connection Strength
 
 
 
1.625
 
  1. Sam S, Ehrmann DA. Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. Diabetologia. 2017 09; 60(9):1656-1661.
    View in: PubMed
    Score: 0.581
  2. Hermanns N, Ehrmann D, Schall S, Maier B, Haak T, Kulzer B. The effect of an education programme (MEDIAS 2 BSC) of non-intensive insulin treatment regimens for people with Type 2 diabetes: a randomized, multi-centre trial. Diabet Med. 2017 08; 34(8):1084-1091.
    View in: PubMed
    Score: 0.142
  3. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Feb; 82(2):524-30.
    View in: PubMed
    Score: 0.140
  4. Hivert MF, Christophi CA, Franks PW, Jablonski KA, Ehrmann DA, Kahn SE, Horton ES, Pollin TI, Mather KJ, Perreault L, Barrett-Connor E, Knowler WC, Florez JC. Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants. Diabetes. 2016 Feb; 65(2):520-6.
    View in: PubMed
    Score: 0.129
  5. Domecq JP, Prutsky G, Mullan RJ, Sundaresh V, Wang AT, Erwin PJ, Welt C, Ehrmann D, Montori VM, Murad MH. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013 Dec; 98(12):4646-54.
    View in: PubMed
    Score: 0.111
  6. Hoffman LK, Ehrmann DA. Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2008 Apr; 4(4):215-22.
    View in: PubMed
    Score: 0.075
  7. Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005 Apr; 54(4):1150-6.
    View in: PubMed
    Score: 0.062
  8. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005 Mar 24; 352(12):1223-36.
    View in: PubMed
    Score: 0.062
  9. Legro RS, Azziz R, Ehrmann D, Fereshetian AG, O'Keefe M, Ghazzi MN. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab. 2003 Nov; 88(11):5137-44.
    View in: PubMed
    Score: 0.056
  10. Azziz R, Ehrmann DA, Legro RS, Fereshetian AG, O'Keefe M, Ghazzi MN. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril. 2003 Apr; 79(4):932-7.
    View in: PubMed
    Score: 0.054
  11. Temple KA, Tjaden AH, Atkinson KM, Barengolts E, Hannon TS, Mather KJ, Utzschneider KM, Edelstein SL, Ehrmann DA, Mokhlesi B. Association of Habitual Daily Physical Activity With Glucose Tolerance and ß-Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study. Diabetes Care. 2019 08; 42(8):1521-1529.
    View in: PubMed
    Score: 0.041
  12. Ehrmann DA. Insulin-lowering therapeutic modalities for polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1999 Jun; 28(2):423-38, viii.
    View in: PubMed
    Score: 0.041
  13. Ehrmann DA. Attenuation of hyperinsulinemia in polycystic ovary syndrome: what are the options? J Endocrinol Invest. 1998 Oct; 21(9):632-5.
    View in: PubMed
    Score: 0.039
  14. Martin KA, Anderson RR, Chang RJ, Ehrmann DA, Lobo RA, Murad MH, Pugeat MM, Rosenfield RL. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018 04 01; 103(4):1233-1257.
    View in: PubMed
    Score: 0.038
  15. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest. 1997 Aug 01; 100(3):530-7.
    View in: PubMed
    Score: 0.036
  16. Lachin JM, Christophi CA, Edelstein SL, Ehrmann DA, Hamman RF, Kahn SE, Knowler WC, Nathan DM. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes. 2007 Apr; 56(4):1153-9.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.